A.R.T. Advisors’s Applied Genetic Technologies Corporation AGTC Stock Holding History

A.R.T. Advisors’s Portfolio AGTC Stock Details AGTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-13,205	Closed	-$55K	–	1723
2019 Q1	$55K	Sell	13,205 -14,037	-52%	-$49.1K	﹤0.01%	1210
2018 Q4	$68K	Buy	+27,242	New	+$160K	﹤0.01%	1198
2017 Q4	–	Sell	-12,585	Closed	-$49K	–	1762
2017 Q3	$49K	Sell	12,585 -42,656	-77%	-$196K	﹤0.01%	1261
2017 Q2	$281K	Buy	55,241 +34,100	+161%	+$192K	0.01%	1026
2017 Q1	$145K	Buy	21,141 +9,300	+79%	+$72.7K	0.01%	1222
2016 Q4	$110K	Buy	+11,841	New	+$107K	0.01%	1141
2016 Q3	–	Sell	-58,960	Closed	-$833K	–	1285
2016 Q2	$833K	Buy	58,960 +31,400	+114%	+$490K	0.04%	616
2016 Q1	$385K	Buy	27,560 +8,100	+42%	+$119K	0.02%	955
2015 Q4	$396K	Buy	19,460 +5,504	+39%	+$84.9K	0.02%	955
2015 Q3	$183K	Buy	+13,956	New	+$232K	0.01%	1179

Other funds holding AGTC

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AGA

Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return

A.R.T. Advisors's AGTC Position: Q2 2019 in Review

A.R.T. Advisors sold out of Applied Genetic Technologies Corporation (AGTC) in Q2 2019, closing a stake of 13,205 shares — an estimated $55K sold.

A.R.T. Advisors first reported a position in AGTC in Q3 2015 and held it in 10 quarters. The position peaked at $833K in Q2 2016. 46 funds tracked by Wall St. Rank hold AGTC as of Q2 2019.

A.R.T. Advisors reported no remaining Applied Genetic Technologies Corporation position as of Q2 2019 after selling out during the quarter.
A.R.T. Advisors sold 13,205 Applied Genetic Technologies Corporation shares in Q2 2019, an estimated $55K.
A.R.T. Advisors first reported a position in Applied Genetic Technologies Corporation in Q3 2015 and held it in 10 quarters.
A.R.T. Advisors's Applied Genetic Technologies Corporation position peaked at $833K in Q2 2016.
46 funds tracked by Wall St. Rank held Applied Genetic Technologies Corporation as of Q2 2019.

Based on A.R.T. Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.